Martí Ramon, Verschuuren Jan J G M, Buchman Alan, Hirano Ikuo, Tadesse Saba, van Kuilenburg André B P, van Gennip Albert H, Poorthuis Ben J H M, Hirano Michio
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Ann Neurol. 2005 Oct;58(4):649-52. doi: 10.1002/ana.20615.
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is caused by mutations in the gene encoding thymidine phosphorylase (TP). All MNGIE patients have had severe loss of TP function and prominent plasma accumulations of the TP substrates thymidine (dThd) and deoxyuridine (dUrd). Here, we report for the first time to our knowledge three MNGIE patients with later onset, milder phenotype, and less severe TP dysfunction, compared with typical MNGIE patients. This report demonstrates a direct relationship between the biochemical defects and clinical phenotypes in MNGIE and supports the notion that reduction of dThd and dUrd accumulation or TP replacement could be useful therapy for MNGIE.
线粒体神经胃肠性脑肌病(MNGIE)由编码胸苷磷酸化酶(TP)的基因突变引起。所有MNGIE患者均存在TP功能严重丧失,且TP底物胸苷(dThd)和脱氧尿苷(dUrd)在血浆中显著蓄积。在此,据我们所知,我们首次报告了3例与典型MNGIE患者相比起病较晚、表型较轻且TP功能障碍不太严重的MNGIE患者。本报告证明了MNGIE生化缺陷与临床表型之间的直接关系,并支持以下观点:减少dThd和dUrd蓄积或进行TP替代可能是治疗MNGIE的有效方法。